Cargando…

BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway

Glioblastoma is the most common type of malignant intracranial tumor in adults. Temozolomide (TMZ), as the first-line chemotherapy agent used in patients with glioblastoma, has demonstrated different effects in patients due to the expression of O6-methylguanine-DNA methyltransferase (MGMT) which is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Mao, Liang, Ruo Fei, Wang, Xiang, Mao, Qing, Liu, Yan Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680702/ https://www.ncbi.nlm.nih.gov/pubmed/29151909 http://dx.doi.org/10.3892/ol.2017.7034

Ejemplares similares

PI3K Inhibition by BKM120 Results in Antiproliferative Effects on Corticotroph Tumor Cells
por: Oliveira, Helen A, et al.
Publicado: (2021)

Regulation of temozolomide resistance in glioma cells via the RIP2/NF‐κB/MGMT pathway
por: Hu, Yu‐Hua, et al.
Publicado: (2021)

Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
por: Peng, Xin, et al.
Publicado: (2021)

Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma
por: Liu, Wei-Lin, et al.
Publicado: (2014)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway
por: Zhang, Peng, et al.
Publicado: (2018)

Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells
por: Ren, Hui, et al.
Publicado: (2016)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
por: Chuang, Fu-Cheng, et al.
Publicado: (2021)

Activity of BKM120 and BEZ235 against Lymphoma Cells
por: Civallero, Monica, et al.
Publicado: (2015)

Inhibitory effect of NVP-BKM120 on cholangiocarcinoma cell growth
por: Padthaisong, Sureerat, et al.
Publicado: (2018)

BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma
por: Zhao, Ping, et al.
Publicado: (2017)

Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
por: Netland, I. A., et al.
Publicado: (2016)

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
por: Anderson, Jennifer L., et al.
Publicado: (2015)

Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines
por: Anjam-Najmedini, Ali, et al.
Publicado: (2022)

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
por: Wang, Dong, et al.
Publicado: (2016)

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells
por: Wang, Lei, et al.
Publicado: (2019)

PLCA8 suppresses breast cancer apoptosis by activating the PI3k/AKT/NF‐κB pathway
por: Mao, Misha, et al.
Publicado: (2019)

Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells
por: Hu, Y, et al.
Publicado: (2015)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
por: Xu, Haoyue, et al.
Publicado: (2022)

Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells
por: Song, Tao, et al.
Publicado: (2015)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2020)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors
por: Ando, Yuichi, et al.
Publicado: (2014)

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
por: PARK, EUNJU, et al.
Publicado: (2011)

BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
por: Speranza, Maria-Carmela, et al.
Publicado: (2016)

Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)
por: Kojima, Takashi, et al.
Publicado: (2022)

LRIG3 Suppresses Angiogenesis by Regulating the PI3K/AKT/VEGFA Signaling Pathway in Glioma
por: Peng, Chenghao, et al.
Publicado: (2021)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest
por: Sadeghi, Soroush, et al.
Publicado: (2020)

Acquired temozolomide resistance in MGMT(low) gliomas is associated with regulation of homologous recombination repair by ROCK2
por: Zhang, Xin, et al.
Publicado: (2022)

Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment
por: Zając, Adrian, et al.
Publicado: (2021)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group
por: Heudel, P-E, et al.
Publicado: (2017)

Exosome-mediated transfer of MIF confers temozolomide resistance by regulating TIMP3/PI3K/AKT axis in gliomas
por: Wei, Q.T., et al.
Publicado: (2021)

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug
por: Caporali, Simona, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6l0odflh19p7oml0u3mhs2oodr